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Background: Optimal patient selection would improve the risk-benefit ratio of natalizumab treatment for
relapsing-remitting multiple sclerosis (RR MS). Clinical features of subjects responding to natalizumab have not
been univocally recognized.
Methods: Longitudinal data on RR MS patients treated with natalizumab in Liguria, Italy are reported. Predictors of
relapse occurrence and disability improvement were analyzed with a logistic regression method in subjects treated
for one year (N = 62). A new score, called “Better EDSS Trend (BET)”, was devised to describe the impact of the
treatment on disability. Changes in annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) after
one and two years and proportion of disease-free patients were evaluated.
Results: Previous EDSS worsening plus ARR ≥ 2 increased the risk of relapse during the treatment [Odds Ratio (OR)
4.12, P = 0.04], but this was not associated with an increase in disability at one year. EDSS 3.0-3.5 or high disease
activity were associated with neurological improvement in the first year of treatment (respectively OR 5.78, P = 0.05
and OR 4.80, P = 0.05). Positive BET score, i.e. improvement in the disability trend, was observed in 40.3% of patients,
and correlated with high ARR in the year before treatment (OR 1.69, P = 0.03).
Conclusion: Subjects with EDSS 3.0-3.5 and those with very active disease in the year before treatment are most
likely to improve in neurological function under natalizumab. A relapse in the first year of treatment is associated to
high pre-treatment disease activity; however, since the occurrence of a relapse did not have a negative impact on
clinical improvement at one year, we suggest that it should not lead to treatment discontinuation. We propose BET
as an additional endpoint of treatment response in MS.
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The marketing of natalizumab (Tysabri, Biogen Idec) for
the treatment of relapsing remitting multiple sclerosis
(RR MS) has been one of the major changes in the treat-
ment of MS in recent years, due to its high efficacy [1].
However, the risk of the severe, sometimes fatal, disease
called progressive multifocal leukoencephalopathy (PML),
in about 2:1000 treated patients raises concerns [2,3]. Op-
timal pre-treatment patient selection is therefore required* Correspondence: glmancardi@neurologia.unige.it
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unless otherwise stated.to minimize the risk-benefit ratio of such treatment. While
longitudinal cohorts of patients treated with natalizumab
have been published so far, results could be biased by is-
sues related to the characteristics of the natural history of
MS before and after initiation of treatment.
Due to the fluctuating course of MS, methodological
pitfalls may affect the analysis of changes in relapse rate.
Published studies on natalizumab effect report a marked
decrease in mean relapse rate in treated patients, com-
pared to pre-treatment (see for instance [4-7]). However,
such phenomenon could be, at least partially, explained
by the regression to the mean phenomenon, which is
observed in patients with high relapse rate (such as in
patients selected for treatment with natalizumab intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of the cohort
Number of MS patients 62
Sex 43 F, 19 M (69.4%–30.6%)




ARR previous year (range) 2.26 (0–6)
ARR previous year,
categorized
0-1 relapse: N = 21; 2 relapses,
N = 22; ≥ 3 relapses, N = 19
Mean EDSS gain in
the year before
+0.41 (SD 1.26)*
Mean baseline EDSS 4.1 (range 0–7.5)
Baseline EDSS, categorized EDSS 0–2.5, N = 16; EDSS 3.0–3.5: N = 15,
EDSS 4.0-5.5: N = 15, EDSS ≥6.0:, N = 16
*Known in 53/62.
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ical trials in MS [8]; alternatively, transition to a second-
ary progressive (SP) course might cause a decrease in
relapse rate over time [9]. Moreover, descriptors used to
characterize the clinical response to natalizumab, like
the change in disability scores over time, appear some-
times inadequate because they do not include an analysis
of the pre-treatment period.
The objective of this study was to analyze and describe
clinical characteristics that might reflect a positive re-
sponse to natalizumab in a cohort of MS patients, to test
a new parameter for evaluating disability changes over
time in MS patients and to provide clinicians and pa-
tients with baseline factors that could influence the
treatment outcome, with a critical attention to methodo-
logical pitfalls.
Methods
The study is composed of two parts. In the first part, we
analyzed the characteristics of the clinical response to
natalizumab in the first two years of treatment; in the
second part, we looked for baseline parameters that
would predict treatment response in the first year. The
cohort was composed of all patients with relapsing MS
treated monthly with natalizumab (300 mg by intraven-
ous infusion) in the Liguria region, North-West of Italy,
for at least one year by November 11, 2010 (N = 62).
These patients had been followed for at least one year
prior to treatment. An additional six patients had been
enrolled in the cohort but interrupted the treatment at
various times before the end of the first year, due to al-
lergic reactions in four patients, “natalizumab inefficacy”
in one patient and presence of anti-natalizumab anti-
bodies in the remaining patient. A “worst scenario” add-
itional analysis was performed assuming that these
patients had been followed for one year of treatment
with a negative outcome. Demographics, disease history,
and clinical data of the 62 patients for the year prior to
treatment were recorded at baseline (Table 1). Follow-up
data were prospectively acquired at 6, 12, and 24 months
after the start of treatment, and included disability, mea-
sured with the Expanded Disability Status Scale (EDSS),
number of relapses, and side effects. At the time of the
analysis, 30 of the 62 MS patients studied had been
treated for at least 12 months and the remainder 32 for
at least 24 months.
For the description of clinical response to natalizumab,
we analyzed the changes in annualized relapse-rate
(ARR) and EDSS for the first and second year of treat-
ment and the proportion of patients with relapses or at
least 1-point of EDSS change compared to baseline.
EDSS scores were acquired in relapse-free phase. We de-
fined “clinically disease free” the subjects without re-
lapses or 1-point EDSS increase during the first year oftherapy. Improvement or stabilization of EDSS after
treatment, compared to baseline EDSS, are usually eval-
uated as markers of response to the therapy. However,
such measures do not consider the EDSS trend in the
pre-treatment period and, therefore, may overestimate
the effect of treatment on disability. Hence, we devised a
new qualitative score as a tool to describe the effect of
the treatment in decreasing the disability gain compared
to the pre-treatment. In detail, we recorded the EDSS
score 12 months before the start of treatment (“EDSS
T-12”), at the start of treatment (“EDSS T0”), and
12 months after the start of treatment (“EDSS T + 12”)
(N = 53 patients). We defined “Better EDSS trend” (BET)
score a qualitative index of the trend in disability course
from one year pre-treatment to one year after treatment.
BET score values would be “1” in case of a decrease by
at least one point in the extent of worsening in EDSS
during the year of treatment as compared to that in the
year prior to treatment, and “0” otherwise. Thus, BET = 1
is taken as (EDSS T0 - EDSS T-12) – (EDSS T + 12 -
EDSS T0) ≥ 1. According to this definition, patients
experiencing stability in the pre-treatment year and
then throughout the first year of treatment have a BET
score = 0. Figure 1 is given as an example.
In the second part of the study, we studied whether
baseline parameters, including demographics and disease
characteristics, were associated with the occurrence of
relapses, disease freedom or BET score in the first year
of treatment, using a logistic regression analysis.
Patients gave informed consent for data on their clin-
ical history and follow-up to be used for the study. The
study was approved by the Ethical Committee of San
Martino University Hospital, Genova.
Statistical analysis
Statistic tests included Wilcoxon matched-pairs signed
rank test, Friedman test for multiple comparisons with
Dunn’s post test, Mann–Whitney test, univariate and
Figure 1 Clinical course before and during natalizumab of
three subjects is displayed. Pt = patient. BET is = 1 in the case of
both patients 15 and 57: Patient 15 worsened by 2 EDSS points in
the year prior to treatment, while in the year following treatment
he/she worsened by less than one EDSS point. Patient 57 worsened
by 0.5 EDSS point in the year prior to treatment, while in the year
following treatment he/she improved by 1.5 EDSS point. In both
cases, patients experienced a decrease by at least one point in
the extent of worsening in EDSS during the year of treatment as
compared to that in the year prior to treatment. In contrast, Patient
12 had stable disability throughout the before and after treatment
periods.
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the SPSS (version 13.0) and GraphPad Prism (version 5)
softwares. A P value < = 0.05 was considered significant.
Results
Relapse rate and disability before and after treatment
Both mean relapse rate and mean disability decreased
significantly in the first year of treatment and remained
stable in the second year. Mean ARR decreased from
2.26 in the year prior treatment to 0.26 in the first year
of treatment (P < 0.0001) in patients treated with at least
12 monthly infusions, and from 2.44 to 0.22 (first year)
and 0.38 (second year) in patients treated for two years
(P < 0.0001) (Figure 2a). About one fourth of the subjects
(16/62 subjects, 25.8%) had a relapse in the first year of
treatment and 9/32 (28.1%) in the second year of treat-
ment. Mean EDSS decreased from 4.1 to 3.6 at the six-
month follow-up and 3.5 at the 12-month follow-up
(P < 0.0001 among baseline and 12-month follow up). A
similar trend was observed in patients treated for two
years and whose mean disability remained stable in
second year of treatment, with the EDSS changing from
3.9 (baseline) to 3.4 (first year) and 3.5 (second year)
(Friedman test P = 0.009 with Dunn’s post test showing
significant difference among baseline and first year)(Figure 2b). Though clinical data, and particularly dis-
ability scores, were acquired in relapse-free phases, we
cannot exclude that baseline EDSS scores may be influ-
enced, in some cases, by recent relapses, since natalizu-
mab is prescribed to patients with active disease in the
pre-treatment.
After one year of treatment, 23/62 (37.1%) patients
had a decrease of EDSS by at least one point compared
to baseline while 2/62 (3.2%) had an increase of EDSS by
at least one point (Figure 2c). After two years, 13/32
(40.6%) had a decreased EDSS score compared to base-
line while 2/32 (6.25%) had worsened (Figure 2d). Free-
dom from clinical disease occurred in 44/62 (71%)
patients in the first year (Figure 2e) and in 22/32 (68.8%)
patients in the second year (Figure 2f ).
About 50% of patients in the first year of treatment
had BET score = 1 (25/53, 47.2%) (Figure 2g) and this
was independent on the occurrence of a relapse during
the same time-period (data not shown). Although there
was a strong association between EDSS improvement
and BET = 1 (χ2 test, P < 0.0001), eight patients had
BET = 1 in the absence of EDSS improvement. Of these,
5 patients had been worsening in the pre-treatment and
were stable during the treatment, while the other 3 had
a less pronounced worsening of disability as compared
to the pre-treatment.
Predictors of treatment response
A. Relapses
We were able to predict the occurrence of a relapse
in the first year of treatment. Specifically, we found
that patients who had experienced more than one
relapse and concomitant worsening of EDSS scale
by at least one point in the year prior to treatment
(i.e. “very active patients”) were more likely to
relapse during the treatment (Odds Ratio 4.12,
95% Confidence interval, 1.05 to 16.23 P = 0.04)
(Table 2 and Figure 3a).
Relapses in the first year of treatment did not
lead to an increase in disability or a lesser clinical
improvement (Figure 3b).
No other single baseline parameter, including sex,
age, disease duration, ARR in the year prior to
treatment, EDSS, or EDSS gain in the year prior to
treatment were associated with the occurrence of a
relapse in the first year of therapy. “Worst scenario”
univariate and multivariate logistic regression
analyses, including the six patients who dropped out
before reaching one year of treatment and assuming
those patients having a relapse during the first
year, did not show an association between high
pre-treatment disease activity and occurrence of
relapses in the first year.
Figure 2 Clinical effect of natalizumab in patients treated with 12 or 24 monthly infusions. a) Changes in annualized relapse rate among
the pre-treatment year and the follow-up, *P < 0.0001; b) Changes in mean EDSS over time *P < 0.0001, §P = 0.009 (Friedman test), °P < 0.05
(Dunn’s post test); c) Percentage of patients with improvement by at least 1 point, worsening by at least one point, or stable EDSS score in the
first year of treatment compared to baseline and d) in the second year; e) Percentage of disease-free patients in the first year and f) in the second
year of treatment; g) percentage of patients with BET = 1 within the first year of treatment.
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High pre-treatment disease activity was significantly
associated with a 1-point EDSS improvement at the
one-year follow-up (Odds Ratio 4.58, 95% Confi-
dence Interval 1.25-16.76, P = 0.02), which was also
predicted by baseline EDSS included between 3.0
and 3.5 (Odds Ratio 6.00, 95% Confidence interval
1.26-28.55, P = 0.02) (Table 3 and Figure 3c). EDSS
improvement was not associated with sex, age, pre-
treatment relapse rate, EDSS worsening in the pre-
treatment year or disease duration. The association
between high pre-treatment disease activity and
EDSS improvement was confirmed by a “worst
scenario” analysis including the six patients who
dropped out before one year, assuming they would
not have an improvement of EDSS under treatment.None of the baseline parameters predicted freedom
from clinical disease in the first year (data not shown).
Higher ARR in the year prior to treatment increased
the possibility of BETscore = 1(Odds Ratio 1.69, 95%
Confidence interval 1.04-2.75, P = 0.03; Mean ARR
in patients with BET=1: 2.60 ± 1.3 vs 1.52 ± 1.2,
Mann–Whitney test P = 0.011) (Table 4 and Figure 3d);
no association was found with other baseline parameters
like baseline EDSS, sex, age, disease duration or with
baseline EDSS class. Due to the formula used to calculate
BET, which included pre-and post-treatment disability
changes, EDSS worsening in the pre-treatment year was
not considered among analyzed baseline parameters.
Results were confirmed by a “worst scenario” analysis
where the six dropped-out patients were assumed to
have BET score = 0 after one year of treatment.
Table 2 Predictors of occurrence of relapse in the first year of treatment
Univariate analysis Multivariate analysis
OR CI P OR CI P
Sex (female vs male) 2.31 0.57–9.32 0.24 - - -
Age 1.00 0.94–1.07 0.88 - - -
Disease duration 1.01 0.92–1.11 0.81 - - -
ARR in the pre-treatment year 0.98 0.63–1.54 0.93 - - -
EDSS gain the pre-treatment year 1.53 0.89–2.62 0.12 - - -
EDSS at baseline 1.25 0.90–1.75 0.18 - - -
EDSS at baseline, categorized 0.62 - - -
3.0 to 3.5 compared to < = 2.5 0.08 0.18–6.44 0.93 - - -
4.0 to 5.5 compared to < = 2.5 1.58 0.29–8.61 0.6 - - -
6 and above compared to < = 2.5 2.60 0.52–13.04 0.24 - - -
High pre-treatment disease activity 4.12 1.05–16.23 0.04 4.12 1.05–16.23 0.04
OR: odds ratio. CI = 95% Confidence Interval.
Univariate and multivariate logistic regression analysis.
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Of the 62 patients analyzed, 40 reported side effects
that did not warrant discontinuation of the treatment,
of which the most frequent were infections (33/62
patients), fatigue (20/62 patients), headache (12/62Figure 3 Baseline predictors of response to natalizumab. a) A relapse
with at least 2 relapses and≥ 1 EDSS gain in the year before starting natali
treatment was not different in patients who had or had not experienced a
frequent in patients with baseline EDSS 3.0-3.5 (§P = 0.02, univariate logistic
pre-treatment relapse-rate compared to those with BET score = 0 (°P = 0.01patients), and musculoskeletal pain (9/62 subjects). One
subject had a recurrence of depressive bipolar disorder
and attempted suicide, recovering well after hospitaliza-
tion and a change in her anti-psychotic treatment. Two
patients were diagnosed with pityriasis rosea.in the first year was more frequent in very active patients, i.e. patients
zumab, *P = 0.04 b) Improvement in EDSS score after one year of
relapse during that time; c) 1-point EDSS improvement was more
regression); d) Patients with BET score = 1 had significantly higher
1).
Table 3 Predictors of 1-point EDSS improvement in the first year of treatment
Univariate analysis Multivariate analysis
OR CI P OR CI P
Sex (female vs male) 1.02 0.33–3.11 0.98 - - -
Age 0.1 0.94–1.51 0.91 - - -
Disease duration 1.00 0.92–1.09 0.91 - - -
ARR in the pre-treatment year 1.3 0.96–1.95 0.21 - - -
EDSS gain the pre-treatment year 1.31 0.83–2.07 0.25 - - -
EDSS at baseline 0.91 0.68–1.22 0.54 - - -
EDSS at baseline, categorized 0.04 0.056
3.0 to 3.5 compared to < = 2.5 6.00 1.26–28.55 0.02 5.78 1.06–31.50 0.04
4.0 to 5.5 compared to < = 2.5 2.00 0.43–9.26 0.37 0.73 0.11–4.8 0.74
6 and above compared to < = 2.5 0.69 0.13–3.75 0.67 0.59 0.08–4.2 0.59
High pre-treatment disease activity 4.58 1.25–16.76 0.02 4.80 1.00–23.08 0.05
OR: odds ratio. CI = 95% Confidence Interval.
Univariate and multivariate logistic regression analysis.
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In this study, we followed a cohort of MS patients
treated with natalizumab for one to two years, with the
aim of identifying the best markers of response to the
treatment and defining the characteristics of responders.
Most published studies on this topic are descriptive
[5,7,10-16]. Few research papers have attempted to cor-
relate baseline data with outcome towards prediction of
treatment response, and results are not always consistent
between studies, possibly due to the methodological
biases that might affect uncontrolled longitudinal
studies. Among predictors of decreased relapse rate,
Fernandez et al. report baseline EDSS lower than 6 [17],
while according to another study, which failed to find an
association with baseline disability categories (similar
ARR under natalizumab in subjects with EDSS 0–3.5Table 4 Predictors of BET score = 1 in the first year of treatme
Univaria
OR CI
Sex (female vs male) 1.18 0.38–3.70
Age 1.02 0.96–1.09
Disease duration 0.98 0.89–1.07
ARR in the pre-treatment year 1.69 1.04–2.75
EDSS gain the pre-treatment year n.a.‡ n.a.
EDSS at baseline 0.91 0.67–1.25
EDSS at baseline, categorized
3.0 to 3.5 compared to < = 2.5 2.00 0.46–8.78
4.0 to 5.5 compared to < = 2.5 3.00 0.62–14.62
6 and above compared to < = 2.5 0.50 0.09–2.64
High pre-treatment disease activity n.a. n.a.
‡: n.a.: not applicable. OR: odds ratio. CI = 95% Confidence Interval.
Univariate and multivariate logistic regression analysis.and subjects with EDSS 3.5–6.5), patients with shorter
disease course have the lowest relapse rate under natali-
zumab [18]. Sargento-Freitas and co-authors found that
patients with “optimal response” to natalizumab (those
with sustained, relapse-independent reduction in EDSS
score of at least 1 point or a reduction in ARR of more
than 1 during NTZ treatment) had higher relapse-rate in
the pre-treatment year compared to those with subopti-
mal or no response to treatment [19]. Prosperini et al.
report that patients with fewer pre-treatment relapses or
lower EDSS are more likely to be disease-free after two
years of treatment [20].
In the cohort we report here, as well as in others pub-
lished so far [4-7], mean ARR decreased to a very low value
after natalizumab (0.26/year). As a consequence, the mag-
nitude of changes in the ARR were directly proportional tont
te analysis Multivariate analysis
P OR CI P
0.78 - - -
0.46 - - -
0.63 - - -
0.03 1.69 1.04–2.75 0.03
n.a. n.a. n.a. n.a.
0.58 - - -
0.19 - - -
0.36 - - -
0.17 - - -
0.41 - - -
n.a. n.a. n.a. n.a.
Laroni et al. BMC Neurology 2014, 14:103 Page 7 of 8
http://www.biomedcentral.com/1471-2377/14/103the pre-treatment disease activity (the higher the relapse
rate in the year prior to treatment, the greater the improve-
ment). This might lead to misleading conclusions, such as
considering natalizumab less effective in subjects with
lower pre-treatment relapse rate (and higher EDSS). There-
fore, we focused our analysis on predictors of relapse oc-
currence. About one-fourth of subjects had a relapse in the
first year of treatment. We found that a high pre-treatment
disease activity, as defined by at least two relapses and con-
comitant 1-point EDSS gain, increased the risk of a relapse
in the first year of therapy, which was independent from
baseline disability. Importantly, the patient population with
a relapse under natalizumab had a similar mean decrease
in EDSS after one year compared to those without relapse:
therefore, relapses upon treatment did not lead to perman-
ent EDSS worsening. If these data will be confirmed in a
longer follow-up, this would differentiate natalizumab from
interferon-beta, since relapses under treatment with inter-
feron beta predict disability accumulation in the long-term
[21]. We did not find predictors of disease freedom under
treatment, differently from what reported by others [20],
possibly due to the different definition of freedom from
disease activity employed in our study (not including mag-
netic resonance imaging data).
High pre-treatment disease activity, as defined above,
was associated to 1-point EDSS decrease after treatment,
similar to what has been reported by the work by Bela-
chew and co-authors [22]. While the same authors did
not find associations between baseline disability and
EDSS improvement, we found that baseline mild-
moderate disability (EDSS 3.0-3.5) was a predictor of
EDSS decrease under treatment; different ways of cat-
egorizing disability classes may explain this.
From the patient’s point of view, the decrease in dis-
ability is not the only relevant endpoint. Stabilization of
disease, as well as slower progression, could significantly
improve the quality of life. This observation prompted
us to create a novel outcome, which we called BET, that
describes an improved EDSS trend in the first year
under treatment, compared to the year prior to treat-
ment. We found that about half treated patients had a
BET score = 1 (improved EDSS trend) after one year of
treatment with natalizumab. We show that BET score =
1 correlated with relapse rate before treatment, indicat-
ing again that subjects with active disease in the pre-
treatment were best responders. Baseline disability did
not influence the BET score. It is important to note that,
since the BET score describes the EDSS trend over time,
it has some limitations associated to the EDSS scale
(i.e. the non-linearity of the disability scale); at the same
time, BET is easy to calculate in clinical practice, where
EDSS is widely used. We suggest that BET score, which
compares disability changes in two subsequent time
frames, could be used as a tool for analyzing the impactof disease-modifying treatments in disability trends com-
pared to the pre-treatment.
Conclusions
In conclusion, we demonstrated that patients who would
most likely improve their neurological status after a one-
year treatment with natalizumab had a high disease activ-
ity in the year prior to treatment, i.e. at least two relapses
and a 1-point increase in EDSS (independent of baseline
disability), or a moderate disability (EDSS 3.0 to 3.5) at the
time of natalizumab initiation. High pre-treatment disease
activity increased the risk of a relapse during the therapy,
but this did not impact upon the overall neurological im-
provement at one year after treatment. Therefore, we sug-
gest that the occurrence of a relapse during natalizumab
should not be considered as treatment failure. We propose
BET score as an additional tool to describe the response to
treatments in MS.
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